
Dr Yvonne Lamb to join Norgine as director of global pharmacovigilance
pharmafile | December 8, 2009 | Appointment | Research and Development, Sales and Marketing | Norgine, appointment, research and development, sales and marketing
Norgine has appointed Dr Yvonne Lamb as director, global pharmacovigilance, with effect from January 25 2010.
A qualified physician, Yvonne has extensive industry experience, serving most recently as pharmacovigilance therapy area head for respiratory at GlaxoSmithKline, prior to which she led the firm’s pharmacovigilance therapy area for neurosciences.
In former roles, she worked in medical evaluation at Roche and as UK medical director at Searle.
She also previously led the UK Clinical Development team for SmithKline Beecham, a role that included a period as medical director for Australia.
Related Content

Norgine enters exclusive licensing agreement with Vir Biotechnology
Norgine has announced its exclusive licensing agreement with Vir Biotechnology, under which Norgine will commercialise …

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …






